Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10377021" target="_blank" >RIV/00216208:11110/18:10377021 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/18:10377021

Result on the web

<a href="https://doi.org/10.3803/EnM.2018.33.2.219" target="_blank" >https://doi.org/10.3803/EnM.2018.33.2.219</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3803/EnM.2018.33.2.219" target="_blank" >10.3803/EnM.2018.33.2.219</a>

Result language

angličtina

Original language name

Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis

Original language description

Background: Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes. Methods: Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin-or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression. Results: A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean follow-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct contact (five trials). No significant heterogeneity was observed among studies (I-2=14.7%, P=0.293). Ezetimibe was associated with a greater reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; P-heterogeneity=0.012). In the meta-regression analysis, the presence of diabetes was associated with a greater reduction of MACE risk when ezetimibe was added to statins (beta=0.87, P=0.038). Conclusion: Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes. Our findings suggest that ezetimibe-statin combination therapy might be a useful strategy in patients with diabetes at a residual risk of MACEs.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

<a href="/en/project/NT13224" target="_blank" >NT13224: The prediction of extension and risk profile of coronary atherosclerosis and their changes during lipid-lowering therapy based on non-invasive techniques.</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Endocrinology and Metabolism

ISSN

2093-596X

e-ISSN

—

Volume of the periodical

33

Issue of the periodical within the volume

2

Country of publishing house

KR - KOREA, REPUBLIC OF

Number of pages

9

Pages from-to

219-227

UT code for WoS article

000436403200011

EID of the result in the Scopus database

2-s2.0-85051354882